- Home
- GES vs KOD Comparison
GES vs KOD Comparison
Compare GES & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GES | KOD |
|---|---|---|
| Founded | 1981 | 2009 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.4M | 795.5M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GES | KOD |
|---|---|---|
| Price | $16.77 | $26.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $19.88 | ★ $22.67 |
| AVG Volume (30 Days) | 520.1K | ★ 761.8K |
| Earning Date | 11-25-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,144,417,000.00 | N/A |
| Revenue This Year | $8.97 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $15.68 | ★ N/A |
| Revenue Growth | ★ 6.44 | N/A |
| 52 Week Low | $8.48 | $1.92 |
| 52 Week High | $17.15 | $28.79 |
Technical Indicators
Market Signals| Indicator | GES | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 63.54 |
| Support Level | $16.74 | $25.44 |
| Resistance Level | $16.85 | $28.79 |
| Average True Range (ATR) | 0.08 | 1.97 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 7.23 | 63.17 |
Price Performance
Historical ComparisonAbout GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.